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Abstract: 1 
Angiopoietins are important growth factors for vascular development and quiescence. They are 2 
promising targets for pro- or anti-angiogenic therapies in diverse pathologies, but the mechanisms of 3 
the ANGPT/TIE2 system are complex and not well understood. The function of the angiopoietins 4 
seems to depend on the specific tissue and on its environment. However, most in vitro experiments 5 
with angiopoietins have been performed with human umbilical vein endothelial cells only. 6 
In the present study, the influence of the angiopoietins was studied with microvascular endothelial 7 
cells (EC’s) originating from different vascular beds, i.e. dermal EC’s and cardiac EC’s, using a recently 8 
developed in vitro angiogenesis model that allows both a quantitative and qualitative evaluation of 9 
the angiogenic cascade. In addition, the expression of the angiopoietins and the receptors, TIE1 and 10 
TIE2 was analyzed with RT-qPCR. 11 
This study revealed that the angiopoietins provoked a differential response in these distinct 12 
endothelial cultures. Both angiopoietin-1 as well as angiopoietin-2 elicited an angiogenic cascade in 13 
the dermal EC’s but not in the cardiac EC’s. In addition, the RT-qPCR data revealed marked 14 
differences in the endogenous expression pattern of these factors, indicating that the origin of 15 
endothelial cells might have an important impact on their angiogenic potential. 16 
Keywords: Angiopoietin, TEK, real time RT-PCR, endothelial cells  17 
18 
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Introduction: 19 
Angiogenesis, the remodelling and expansion of a pre-existing vascular network is crucial for 20 
development. In the adult it is confined to the cyclic ovarium, the mammary gland and to the 21 
placenta, but it is activated during wound healing or in diverse pathological situations including 22 
tumorigenesis, ischemic disease, chronic inflammation and other cardiovascular diseases [1, 10, 17]. 23 
As a consequence, both pro- and anti- angiogenic treatments are promising therapeutic strategies for 24 
a range of pathologies. However, the process of angiogenesis is highly complex, and a better 25 
knowledge of the molecular mechanisms of angiogenesis will aid the development of future 26 
therapies that aim to enhance or inhibit angiogenesis [9]. 27 
A range of growth factors have already been described to influence the process of angiogenesis. One 28 
of the most important and best known amongst them is the vascular endothelial growth factors 29 
(VEGF). VEGF induces capillary sprouting by stimulating endothelial migration and proliferation. Due 30 
to its importance in both development and in various pathological situations, VEGF has been 31 
extensively studied in the past decades [23]. The angiopoietins are another family of endothelial 32 
specific growth factors. Their role during angiogenesis is still elusive, they are expressed in a range of 33 
developing and adult tissues [11, 12, 16], and it is currently hypothesised that the angiopoietins play 34 
a major role during the maturation of the vasculature following VEGF induced angiogenesis [2, 25]. 35 
Angiopoietin 1 (ANGPT1) and angiopoietin 2 (ANGPT2) are the most common and best described 36 
members of the angiopoietin family. These ligands both bind the endothelial specific TIE2 receptor 37 
[27]. ANGPT1 is described as a vascular maturation factor; it induces lumen formation and vascular 38 
quiescence by activating the TIE2 receptor. ANGPT2 is an antagonist of ANGPT1, as it binds the TIE2 39 
receptor with similar affinity as ANGPT1, but it has a weak ability to activate TIE2 [7, 22]. In this way, 40 
ANGPT2 induces vascular destabilisation, which can either lead to the onset of angiogenesis or 41 
endothelial regression, depending on the presence or absence of VEGF respectively. However, the 42 
antagonistic action of ANGPT2 seems to be context and tissue dependent [25]. Recent data indicates 43 
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that ANGPT-TIE2 activation is regulated by the TIE1 receptor [27]. This TIE1 receptor is another 44 
endothelial specific receptor that is structurally highly similar to TIE2, but does not interact directly 45 
with the angiopoietins [22].  46 
Most of the current knowledge on how the angiopoietins influence angiogenesis has been deduced 47 
from complex in vivo models with loss of function or gain of function mutations. These models are 48 
often lethal in the embryonic stage of development and hardly provide the possibility to investigate 49 
the mechanism in real time [5]. In vitro models of angiogenesis might provide an alternative, as these 50 
experiments are more standardized and can be monitored in real time. Various in vitro models of 51 
angiogenesis have been described. However, in most of these models, only a single stage of the 52 
angiogenic cascade is investigated, e.g. proliferation, migration or tube formation. Recently, an all-in-53 
one angiogenesis assay has been developed that allows both the qualitative and quantitative 54 
assessment of the entire angiogenic cascade [3, 4, 6]. Until now, the majority of in vitro angiogenic 55 
models have been developed with human umbilical venous endothelial cells (HUVEC), because these 56 
cells are relatively easy to isolate and grow [29]. However, since in vivo angiogenesis mostly proceeds 57 
in the microvasculature, it would be more appropriate to investigate in vitro models with 58 
microvascular endothelial cells [29]. 59 
 In the present study, the influence of exogenously administered ANGPT1 and ANGPT2 was 60 
investigated in the all-in-one angiogenesis model applied to microvascular endothelial cells derived 61 
from the human heart and neonatal foreskin. In addition, RT-qPCR was performed to map the 62 
endogenous expression of the angiopoietins and their receptors TIE1 and TIE2 at different stages 63 
during the angiogenic cascade. 64 
65 
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Materials and methods: 66 
Human endothelial cells and media 67 
Human microvascular endothelial cells either derived from the heart muscle of a 54 year old female 68 
(HCMEC), or from the neonatal foreskin (HDMEC) were purchased from Lonza Biosciences (Verviers, 69 
Belgium; original catalogue names: HMVEC-C Cardiac MV Endo Cells and HMVEC-dBlNeo, 70 
respectively). A basal medium (BM) was constituted by using the growth EBM-2 medium (Lonza 71 
Bioscience, Verviers, Belgium), to which 2% foetal bovine serum was added. This medium 72 
composition retains cell survival, but does not result in an angiogenic response of the cells. The 73 
growth medium (GM) consisted of the EBM-2 medium, supplemented with several growth factors as 74 
provided with the EGM-MV Bullet kit (Lonza Biosciences). This kit included Vascular Endothelial 75 
Growth Factor A (VEGF-A), Fibroblast Growth Factor 2 (FGF-2), Epidermal Growth Factor (EGF), 76 
Insulin-like Growth Factor 1 (IGF-1), hydrocortisone and some less specified components such as 77 
bovine brain extract and foetal bovine serum. Previous studies revealed that this medium stimulates 78 
endothelial cells to run chronologically through all phases of the angiogenic cascade in vitro within 30 79 
- 40 days (Table 1) [6]. 80 
The growth factors ANGPT1 (CYT-413; Biotrend Chemikalien GmbH, Köln, Germany) and/or ANGPT2 81 
(CYT-414; Biotrend Chemikalien GmbH, Köln, Germany) were added to the media at a concentration 82 
of 100 ng/ml, as previously determined [28]. In a preliminary study no angiogenic or antiangiogenic 83 
effect could be observed of ANGPT1 or ANGPT2 when these were administered at a concentration of 84 
50 ng/ml, whereas application of both growth factors at concentrations of 100 or 200 ng/ml led to 85 
angiogenic effects (unpublished data).  86 
In vitro angiogenesis assay 87 
Endothelial cells were seeded in gelatine-coated 24-well plates (Iwaki, Tokyo, Japan) at a 88 
concentration of 4.1-4.5 x 104 cells per well. The angiogenic effects of the different experimental 89 
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treatments were investigated by staging the angiogenic cascade in vitro, according to a previously 90 
established method [2, 3]. On the first day of investigation, 4 visual fields were randomly allocated 91 
and defined by coordinates. Phase contrast micrographs were obtained from these visual fields, 92 
using an Axiovert 25 inverted microscope (Zeiss, Jena, Germany) with an Inteq 000610 video camera 93 
(Inteq, Berlin, Germany) and the image editing system Axiovision, version 3.0 (Zeiss). Based on the 94 
morphology of the endothelial cells, these micrographs were assigned to the respective stage of 95 
angiogenesis in vitro, as previously described (Table 1) [6].  96 
Quantification of angiogenesis in vitro, induced by ANGPT1 and ANGPT2 was carried out as follows: 97 
For each cell culture, six experimental groups were cultivated, i.e. three in GM and three in BM. In 98 
the first group, only ANGPT1 was added, in the second group, only ANGPT2 was added and in the 99 
third group, both factors were added in combination to the medium. In addition, cells were cultured 100 
in BM as negative controls and in GM as positive controls. The documentation of the visual fields was 101 
performed twice a week over 60 days (17 investigation days). For each visual field, the sum of 102 
assigned stages at the 17 investigation days (S) was calculated. The angiogenic effects of ANGPT1, 103 
ANGPT2 or their combination were determined by calculating the ratio of the arithmetic mean of the 104 
sums of the visual fields of each treatment ( factorgrowthS ) [3]. Analysis of variance was performed 105 
with the Sigmaplot software (Systat, Erkrath, Germany). 106 
RT-qPCR  107 
Total RNA was isolated with the Invisorb Spin Cell RNA Mini Kit (Invitek, Berlin, Germany) from cells, 108 
sampled in duplicate after 3, 10, 20 and 40 days in culture. RNA integrity was analyzed with the 109 
Experion™ Automated Gel Electrophoresis System (Bio-Rad, Nazareth, Belgium), using the Experion™ 110 
mRNA Std Sense chips (Bio-Rad) according to the manufacturers protocol. The Experion system uses 111 
an algorithm to analyze RNA-integrity on a scale from 1 to 10, with 1 being totally degraded RNA and 112 
10 being totally intact RNA. The isolated RNA was reverse transcribed with the First Strand cDNA 113 
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Synthesis Kit (Fermentas, Leon-Rot, Germany) and qPCR was performed with the Rotor Gene 6000 114 
(Corbett) using Maxima™ SYBR Green/Fluorescein qPCR Master Mix (Fermentas). All samples were 115 
run in duplicate and each run included a serial 5-fold dilution of a pooled cDNA mix from all samples 116 
to calculate the standard curve. Gene specific primers (table 2 & 3) were either used as described by 117 
other researchers, or designed using RTprimerDB [21]. The technical details of these assays have 118 
been uploaded on RTprimerDB and are freely accesible [21]. 119 
Sample normalization was performed with the 4 most stable reference genes, i.e. GAPDH, UBC, TBP 120 
and HPRT, identified from a set of ten reference genes as described before [6]. Normalized relative 121 
quantities of mRNA coding for ANGPT1, ANGPT2, TIE2 and TIE1 (table 1) were calculated using the 122 
REST-software (Qiagen, Hilden, Germany) [13] and the qBase-software [15]. The REST software 123 
analyses if gene-expression is significantly different between two sample groups using bootstrap 124 
randomization [13].The qBase software calculates normalized relative expression quantities which 125 
can then be further used for statistic analysis with Sigmaplot (Systat). 126 
Results: 127 
Angiogenesis assay 128 
Endothelial cells, incubated in BM remained in stage 1 of angiogenesis in vitro. In contrast, 129 
incubation of the endothelial cells in GM, led to a run through all stages of angiogenesis in vitro. The 130 
response to the addition of angiopoietins was different between both cell types. Addition of the 131 
angiopoietins in HCMEC cultures led to a moderate angiogenic response (Fig. 1 and 2), in which the 132 
cultures did not go beyond stage 3 of angiogenesis in vitro, whereas addition of the angiopoietins in 133 
HDMEC cultures led to an angiogenic response (Fig. 3 and 4). After 20 days, the HDMEC’s formed a 134 
network, but this network remained in a two dimensional state. Addition of GM led to higher cell 135 
densities in both HCMEC as well as in HDMEC cultures, but no additional effect on the angiogenic 136 
process was observed. 137 
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The sum of assigned stages are listed in table 4, for HDMEC’s and for HCMEC’s, cultured in GM was 138 
GMS = 78 ± 1.83; GMS = 68.50 ± 2.83, respectively. Addition of ANGPT1 in BM to HDMEC cultures, 139 
resulted in a 1ANGPTS = 59.75 ± 0.50, which was significantly lower than ANPT1 in GM 1ANGPTS = 140 
63.25 ± 1.71 (P-value <0.05). Addition of ANGPT1 in HCMEC cultures lead to a significantly lower 141 
response in BM ( 1ANGPTS = 31.25 ± 1.71) as compared to GM ( 1ANGPTS = 34.00 ± 0.00, P-value < 142 
0.05). Addition of ANGPT2 did not result in a significantly different response between BM and GM in 143 
either of the cell types, but it was significantly different between HDMEC’s in GM ( 2ANGPTS = 62.25 ± 144 
0.96) and HCMEC’s in both BM ( 2ANGPTS = 29.00 ± 10.30; P-value < 0.05) as well as in GM ( 2ANGPTS = 145 
19.50 ± 2.65; P-value < 0.05). The addition of both ANGPT1 as well as ANGPT2 to the medium 146 
resulted in a significant difference between HDMEC’s in GM ( 2&1 ANGPTANGPTS =62.00 ± 1.41) and 147 
HCMEC’s in GM ( 2&1 ANGPTANGPTS =19.25 ± 1.26; P-value < 0.05), but not between the other 148 
treatments. 149 
RT-qPCR 150 
The RNA quality indicator (RQI) varied between 9.5 and 8.5 for all samples, indicating that RNA 151 
degradation during processing was minimal [14]. The comparison of the combined gene expression 152 
between the different cell types with the REST software (Qiagen) revealed significant differences in 153 
gene expression between these cell types. ANGPT2 mRNA was significantly down-regulated in 154 
HCMEC’s compared to HDMEC’s, by a mean factor of 0.019 (S.E. range is 0.004 – 0.098; P-value < 155 
0.05) whereas ANGPT1 mRNA was significantly up-regulated in HCMEC’s compared to HDMEC’s, by a 156 
mean factor of 3595.302 (S.E. range is 161.197 - 63881.461; P-value < 0.05) (Fig. 5). No significant 157 
difference was found for TIE2 mRNA expression between the two cell types. In contrast, TIE1 mRNA 158 
was less abundant in HCMEC’s as compared to HDMEC’s, by a mean factor of 0.308 (S.E. range is 159 
0.085 – 1.231; P-value < 0.05) (Fig. 5).  160 
 9 
 
Gene expression was also time dependent in the both cell cultures. Expression of ANGPT2 mRNA in 161 
HDMEC’s was positively correlated with length of cultivation (P-value = 0.004; R^2 = 0.771). 162 
Expression of mRNA for ANGPT1 was not detected in de HDMEC’s cells, after 3 and 10 days of 163 
culture, but it became expressed after 20 and 40 days of culture (figure 6). TIE2 expression in 164 
HCMEC’s was negatively correlated with increasing days in culture (P-value = 0.004; R^2 = 0.767), and 165 
TIE1 expression was stably expressed in both cultures between days 3 to 20, but after 40 days of 166 
culture, it was downregulated in both cultures (Fig. 7). 167 
Discussion: 168 
The angiopoietins, i.e. ANGPT1 and ANGPT2 are important angiogenic growth factors. They are 169 
crucial for the normal development of the vasculature, but are also implicated in diverse 170 
cardiovascular pathologies [33]. The complex interactions between ANGPT1 and ANGPT2, and their 171 
exact function are still elusive, and seem to depend on the tissue environment [2]. In the present 172 
study, the effect of the angiopoietins was tested in a recently developed in vitro angiogenesis assay, 173 
which has previously been established to allow the quantitative assessment of the whole angiogenic 174 
cascade, without the use of an external extracellular matrix [3, 6]. 175 
ANGPT2 is frequently viewed as an antagonist to the function of ANGPT1 through competitive 176 
binding on the TIE2 receptor [26]. However, its function seems to be context dependent, and in 177 
certain situations, ANGPT2 has been observed to induce angiogenesis through the activation of TIE2 178 
[25]. In the present study, the pro-angiogenic effects of ANGPT2 were similar to those of ANGPT1 179 
and to those of the combination of ANGPT1 and ANGPT2, suggesting that ANGPT2 does not act as an 180 
antagonist to ANGPT1 in this in vitro setting. Conflicting data exists about the capacity of ANGPT2 to 181 
induce TIE2 activation in vitro [22, 32]. The action of the angiopoietins is thought to depend on 182 
interactions between TIE2 and TIE1 [18, 19], and these complex interactions are since long a subject 183 
of debate [2, 33]. Recent evidence has revealed that homodimerization and activation of TIE2 is 184 
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inhibited through the formation of TIE1-TIE2 heterodimers, in which TIE1 might function as an 185 
inhibitory co-receptor [27]. ANGPT1 is able to break the association of the TIE2-TIE1 heterodimers, 186 
and to induce homodimerization of two TIE2’s, resulting in receptor activation. In contrast, ANGPT2 187 
is not able to break these heterodimers, and is unable to activate the TIE2 receptor when it is 188 
associated with TIE1 [27]. ANGPT2 is able to induce TIE2 activation in HUVEC’s with experimentally 189 
downregulated TIE1 expression, suggesting that ANGPT2 is able to activate the TIE2 receptor and 190 
that it might have similar effect as ANGPT1 in the absence of TIE2-TIE1 heterodimers [19]. However, 191 
in endothelial progenitor cells, which both express TIE1 and TIE2, ANGPT2 is able to activate TIE2, 192 
because no heterodimers are formed in these cells [19]. In the present study, the expression of 193 
mRNA for both TIE2 and TIE1 was detected in HDMEC’s and HCMEC’s. The mRNA of TIE2 was 194 
expressed at similar levels in both cell types, whereas mRNA of TIE1 was more abundant in HDMEC’s 195 
in comparison to the HCMEC’s. This might suggest that a differential TIE1/TIE2 ratio in the cells might 196 
cause a different effect of Angiopoietins. In vivo, TIE1 is expressed at sites of active angiogenesis and 197 
at vascular branching points and bifurcations, whereas it is absent in stables vessels [20, 24]. This 198 
expression pattern indicates that the presence of TIE1 activates the vasculature by inhibiting TIE2 199 
activation, whereas the absence of TIE1 might allow both ANGPT1 and ANGPT2 to activate TIE2 and 200 
to induce maturation and vascular quiescence [27]. In the present study, the higher expression 201 
pattern of TIE1 in the HDMEC’s support this hypothesis, as these factors are angiogenically more 202 
active as compared to the HCMEC’s that had a lowered expression of TIE1. 203 
Although ANGPT1 is known as a vascular maturation factor, it has also been observed to be a pro-204 
angiogenic compound in certain situations [8, 30]. In the present study, both the addition of ANGPT1, 205 
ANGPT2 and their combined addition stimulated an angiogenic cascade in the HDMEC cultures with 206 
basic medium. However, in the cultures with growth medium, it seemed to stabilize the ongoing 207 
angiogenesis as these cultures only attained stage four of the angiogenic cascade. These results 208 
indicate that the action of the angiopoietins might depend on the presence or absence of other 209 
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growth factors in the medium such as fibroblast growth factor, or endogenously expressed growth 210 
factors. In HCMEC’s, both the addition of ANGPT1, ANGPT2 and the combination of both factors 211 
resulted in an anti-angiogenic response, suggesting that the action of the Angiopoietins might be 212 
dependent on the cell type. 213 
The different angiogenic potential of these EC’s of distinct origin may also be explained by a 214 
differential endogenous mRNA-expression pattern of the endothelial cells. ANGPT1 was highly 215 
expressed in the HCMEC, whereas this factor was not expressed in the early stages of angiogenesis of 216 
the HDMEC and became only expressed at low levels in the later stages of angiogenesis. In contrast, 217 
ANGPT2 was only expressed at basal levels in the HCMEC whilst being highly upregulated in the 218 
HDMEC’s. This might indicate that the HDMEC are more prone to an angiogenic response due to a 219 
higher expression of endogenous ANGPT2, and a low expression of ANGPT1, resulting in an inhibition 220 
of TIE2 mediated stabilization of the endothelial cells. A previous study with the same cells has also 221 
revealed a significant difference in the expression pattern of mRNA for the VEGF-receptor VEGFR1 222 
[6], indicating that endothelial cells of different origin might respond differently to a given stimulus,  223 
and that care should be taken when results of angiogenic tests on a specific vascular bed are 224 
extrapolated to another vascular bed.   225 
In conclusion, the present study revealed that angiopoietins are able to provoke an angiogenic 226 
response in microvascular endothelial cell cultures. However, their effect might be highly dependent 227 
on the tissue environment and on the origin of the endothelial cells. The use of multiple endothelial 228 
cell lines with different origins should be supported, to aid the extrapolation of in vitro data to in vivo 229 
situations.  230 
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Tables: 327 
Table 1: stages of angiogenesis in vitro, and description of cell morphology within the different stages  328 
Stage Nr. Morphology of endothelial cells 
Stage 1 
Confluent monolayer 
Polygonal shaped cells 
Stage 2 
Endothelial sprouting, late phase 
> 50% elongated shaped cells 
Stage 3 
Linear side by side arrangement, late phase 
> 50% linearly arranged cells 
Stage 4 
Networking 
Network of linearly arranged cells 
Stage 5 
Three-dimensional organisation, early phase 
Appearance of capillary-like structures (linear structures of endothelial cells with a 
diameter of more than 28 µm; for these structures an internal lumen was shown by 
electron microscopy) 
Stage 6 
Three-dimensional organisation, late phase 
All linearly arranged cells form capillary-like structures; dissolution of the cell layer 
on the bottom 
 329 
330 
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Table 2: Primers, used for RT-qPCR 331 
Gene Primer sequence (5'-3') amplicon length (bp) Ta (°C) Genbank accession nr or reference RTprimerdB ID
ANGPT1 F GGACAGCAGGAAAACAGAGC 129 60 NM_001146.3 8190
R CACAAGCATCAAACCACCAT
ANGPT2 F ACTGTGTCCTCTTCCACCAC 132 60 NM_001118888.1 8191
R GGATGTTTAGGGTCTTGCTTT
Tie2 F GCTTGCTCCTTTCTGGAACTGT 112 60 [27] 2636
R CGCCACCCAGAGGCAAT
Tie1 F AGA ACCTAG CCT CCA AGATT 119 60 NM_005424 8212
R ACT GTA GTT CAG GGA CTC AA
332 
 333 
Table 3: Full official gene names 334 
official symbol alias name
ANGPT1 ANG1 Angiopoietin 1
ANGPT2 ANG2 Angiopoietin 2
Tie-1 TIE1 tyrosine kinase with immunoglobulin-like and EGF-like 
domains 1
TEK TIE2 TEK tyrosine kinase, endothelial  335 
 336 
 337 
 338 
 339 
 340 
 341 
 342 
343 
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Table 4: sum of stages of the different treatments 344 
Cell type Visual 
field     
S
ANGPT1, BM 
S
ANGPT2, BM
S
ANGPT1 & ANGPT2, BM
S
ANPT1, GM
S
ANGPT2, GM
S
ANPT1 & ANGPT2, GM
1 60 59 55 61 62 60
2 60 59 57 64 63 63
3 59 59 60 63 61 63
4 60 60 61 65 63 62
mean 59.75 ± 0.50 59.25 ± 0.50 58.25 ± 2.75 63.25 ± 1.71 62.25 ± 0.96 62.00 ± 1.41 
1 33 41 23 34 20 21
2 32 34 29 34 23 18
3 29 19 37 34 17 19
4 31 22 19 34 18 19
mean 31.25 ± 1.71 29.00 ± 10.30 27.00 ± 7.83 34.00 ± 0.00 19.50 ± 2.65 19.25 ± 1.26 
HDMEC
HCMEC
345 
 346 
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Figures: 348 
 349 
Figure 1: Micrographs of human cardiac microvascular cells (HCMEC) after 40 days in culture with 350 
either ANGPT1 in BM (A), ANGPT2 in BM (B), ANGPT1 & ANGPT2 in BM (C), ANGPT1 in GM (D), 351 
ANGPT2 in GM (E), ANGPT1 & ANGPT2 in GM (F). No clear network formation is evident in any of the 352 
treatments. HCMEC, grown in GM attain higher cell densities. Bars: 50µm. 353 
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 355 
Figure 2: Stages of angiogenesis in vitro of HCMEC. Addition of ANGPT1, ANGPT2, or the combination 356 
of these factors did not lead to an angiogenic cascade. 357 
358 
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 359 
Figure 3: Micrographs of human dermal microvascular cells (HDMEC) after 40 days in culture with 360 
either ANGPT1 in BM (A), ANGPT2 in BM (B), ANGPT1 & ANGPT2 in BM (C), ANGPT1 in GM (D), 361 
ANGPT2 in GM (E), ANGPT1 & ANGPT2 in GM (F). Network formation is evident in all of the cell 362 
cultures. However, in the cultures with GM, this is less clear, because of an overall higher cell density 363 
in these cultures. Bars: 50µm. 364 
 365 
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 366 
Figure 4: Stages of angiogenesis in vitro of HDMEC. The addition of ANGPT1, ANGPT2 or the 367 
combination of these factors led to an angiogenic cascade that halted at stage four of angiogenesis in 368 
vitro.  369 
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Figure 5: Combined expression pattern of the angiopoietins and TIE2 in the HDMEC’s and the 371 
HCMEC. Error bars: SEM. 372 
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 375 
Figure 6: Expression pattern of ANGPT1 and ANGPT2 at different culture days in the HDMEC’s and in 376 
the HCMEC. Error bars: SEM. 377 
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Figure 7: Expression pattern of TIE2 at different culture days in the HDMEC’s and in the 379 
HCMEC. Error bars: SEM. 380 
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